Prevalence of underlying cirrhosis etiologies in hepatocellular carcinoma patients of Hispanic versus non-Hispanic ethnicity.

Authors

null

Jeremy Chang

UC San Diego, La Jolla, CA

Jeremy Chang , Veeral Ajmera , Kathryn J Fowler , Stephanie Ting , Pablo Tamayo , Adam Burgoyne

Organizations

UC San Diego, La Jolla, CA, UC San Diego, San Diego, CA, University of California San Diego Department of Radiology, San Diego, CA, UC San Diego Moores Cancer Center, San Diego, CA, Univ Of California-San Diego School of Medcn, San Diego, CA

Research Funding

No funding received

Background: While the incidence and rates of mortality are in decline for the vast majority of cancers, those of hepatocellular carcinoma (HCC) continue to increase. Forecasts from the Surveillance, Epidemiology, and End Results (SEER) database suggest that the Hispanic population will have the highest incidence rate of HCC in the United States by the end of this decade. As a result, further studies are needed to identify specific risk factors for the development of HCC in this ethnic group. Methods: This was a retrospective, single center study conducted in Southern California to identify the prevalence of underlying cirrhosis etiologies in HCC patients of Hispanic versus non-Hispanic ethnicity. Causes of cirrhosis included nonalcoholic fatty liver disease (NAFLD), viral hepatitis, alcohol, and other chronic liver disease. The designation of NAFLD cirrhosis was assigned to patients in whom there was an exclusion of viral hepatitis B, viral hepatitis C, significant alcohol consumption, other etiology of chronic liver disease, and who had the presence of fatty liver on imaging or were diagnosed with cirrhosis with a concomitant metabolic risk factor (diabetes mellitus, hypertension, hyperlipidemia, or obesity). Results: A total of 165 patients were included in this study. There were 57 patients of Hispanic ethnicity and 108 patients of non-Hispanic ethnicity. No significant differences in age or gender were found between the two groups. When analyzing the prevalence of cirrhosis etiologies, 17 patients (29.8%) of Hispanic background were found to have underlying NAFLD cirrhosis compared to 10 patients (9.3%) of non-Hispanic background (p = 0.001). In contrast, 67 patients (62%) in the non-Hispanic group had diagnoses of cirrhosis associated with viral hepatitis B or C compared to 22 patients (38.6%) in the Hispanic group (p = 0.005). There was no significant difference in the prevalence of alcoholic cirrhosis (24.6% vs 13%, p = 0.08), cirrhosis due to other chronic liver disease (1.8% vs 2.8%, p = 1), or HCC without cirrhosis (5.3% vs 13%, p = 0.178) between Hispanic and non-Hispanic patients, respectively (Table). Conclusions: There were significantly higher rates of NAFLD cirrhosis identified in HCC patients of Hispanic ethnicity compared to those of non-Hispanic ethnicity. With the continually rising incidence rate of HCC in this patient group, it is important for providers to be aware of this association so that appropriate surveillance and prevention strategies may be pursued.

Hepatocellular carcinoma patient characteristics.

Characteristics
Hispanic Ethnicity
Non-Hispanic Ethnicity
p-value
Number of Patients
57
108

Median Age (Years)
66
68

Male Gender
46 (80.7%)
78 (72.2%)
0.26
Cirrhosis Etiology



NAFLD
17 (29.8%)
10 (9.3%)
0.001
Viral Hepatitis
22 (38.6%)
67 (62%)
0.005
Alcohol
14 (24.6%)
14 (13%)
0.08
Other
1 (1.8%)
3 (2.8%)
1
None
3 (5.3%)
14 (13%)
0.178

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2022 ASCO Annual Meeting

Session Type

Publication Only

Session Title

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Track

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Sub Track

Hepatobiliary Cancer

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr e16163)

DOI

10.1200/JCO.2022.40.16_suppl.e16163

Abstract #

e16163

Abstract Disclosures

Similar Abstracts

First Author: Jeremy Chang

First Author: Biwei Gao

First Author: Moses Andrew Alfaro